Trials / Temporarily Not Available
Temporarily Not AvailableNCT00215813
Ampligen in Chronic Fatigue Syndrome
An Open-Label Study Of Poly I:Poly C12U (AMPLIGEN®) in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)
- Status
- Temporarily Not Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- AIM ImmunoTech Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This is an open label study of Ampligen in patients with chronic fatigue syndrome.
Detailed description
An Open-Label Study of Poly I: Poly C12U (Ampligen®) in Patients with Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME). The FDA approved the study for cost recovery. Patients enrolled in the study are responsible for costs related to the therapy, e.g., drug cost, infusion cost, cost of supplies, diagnostic and other laboratory testing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Poly I: Poly C12U (Rintatolimod) | 200-400 mg IV infusions given twice weekly over a period of 30-60 minutes |
Timeline
- First posted
- 2005-09-22
- Last updated
- 2025-10-29
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00215813. Inclusion in this directory is not an endorsement.